Latest Mash News

Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Saferoads Holdings Limited reported a modest rise in quarterly sales and a half-year net profit of approximately $511k, while progressing regulatory approval for its innovative HV2 barrier.

Saferoads Holdings Limited reported a solid quarterly profit of $346,000, driven by strong product sales including a key order from On-site Rentals. However, the company signals caution on sustaining profitability due to market uncertainties and inventory adjustments.